The Company is currently focusing its product development and commercialization efforts on its lead product candidate, FluMist, an investigational live virus vaccine for influenza delivered as a nasal spray. Its goal is to become a leader in the discovery, development, manufacture and marketing of innovative vaccines which are safe, effective and economical enough to merit their use in immunization programs targeting the general population. Its vaccine programs are based both on techniques for producing weakened live virus vaccines and on its proprietary genetic engineering technologies.
Revenues reflect a decrease in sales of vaccines.
All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.